MedTrace Logo

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD2516 to Healthy Volunteers

NCT00754715 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2008-12-15

No results posted yet for this study

Summary

The primary purpose of this study is to assess the safety and tolerability of AZD2516 following administration of a single dose.

Conditions

  • Healthy

Interventions

DRUG

AZD2516

Solution administered once orally

DRUG

Placebo

Solution administered only once

Sponsors & Collaborators

Principal Investigators

  • Bo Fransson, MD · AstraZeneca

  • Lars Ståhle, MD, PhD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2008-11-30
Completion
2008-12-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00754715 on ClinicalTrials.gov